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Abstract
Synthesis of influenza virus mRNA by the viral RNA polymerase complex is primed by capped RNA fragments generated by endonuclease
cleavage of host pre-mRNA by the polymerase subunit PB1. In previous studies, endonuclease and promoter-binding sites have been described in
the C-terminal region of PB1. Here, we have identified an additional region near the C-terminus of PB1 involved in producing capped RNA
primers for viral transcription. In particular, mutations of basic amino acids K669, R670, and R672 inhibited primer-dependent viral mRNA
synthesis. In contrast, primer-independent cRNA and vRNA syntheses were only marginally affected. Additionally, recombinant viruses
containing the K669A or R672A mutations expressed reduced amounts of mRNA compared to cRNA during infection and were attenuated in cell
culture. Further in vitro analysis showed that these mutations inhibited the ability of the polymerase to initiate mRNA synthesis by causing a
reduction in binding to the vRNA promoter and capped RNA. These results suggest that this region plays a critical role in the regulation of viral
mRNA transcription.
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Influenza A virus is a negative strand RNA virus belonging
to the Orthomyxoviridae family (reviewed in Palese and Shaw,
2007). The viral genome is comprised of eight segments of
negative strand viral RNA (vRNA) packaged into ribonucleo-
protein (RNP) complexes, each containing an RNA segment
bound by the viral RNA-dependent RNA polymerase and nu-
cleoprotein (NP). The influenza polymerase, a trimeric complex
containing the polymerase basic proteins 1 and 2 (PB1 and PB2)
and the polymerase acidic protein (PA), performs both tran-
scription and replication of the viral genome within RNP
complexes (reviewed in Neumann et al., 2004). Viral transcrip-
tion (vRNA→mRNA) is primed by capped RNA fragments
produced by endonuclease cleavage of host mRNAs 9–15 nt⁎ Corresponding author. Fax: +44 1865275556.
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doi:10.1016/j.virol.2007.11.030from the cap structure (Plotch et al., 1979, 1981). All three of
the polymerase subunits are involved in the production of
capped RNA primers, specifically PB2 binds to the cap
structure (Blaas et al., 1982; Fechter et al., 2003; Ulmanen et
al., 1981) and PB1 is reported to contain the endonuclease
active site (Li et al., 2001). However, the process of
endonuclease cleavage is more complicated than previously
thought, with Fodor et al. (2002) and Hara et al. (2006)
indicating a role for the PA subunit. Replication is performed
via a complementary intermediate (cRNA) which is subse-
quently used as a template for vRNA synthesis (vRNA→cR-
NA→ vRNA) (Neumann et al., 2004). In contrast to
transcription, replication is primer independent and generates
uncapped RNA without polyadenylated 3′ ends.
The PB1 subunit contains the polymerase active site, the
highly conserved motifs characteristic of RNA-dependent
RNA polymerases, in its central region (see Fig. 1) (Biswas
and Nayak, 1994). Adjacent to this region are two nucleotide-
binding sites proposed to be involved in a two-site mechanism of
Fig. 1. A diagrammatic representation of the influenza polymerase basic protein
1 (PB1). The known functional domains are labeled (see text for references).
Scale indicates residue number from amino terminus.
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et al., 2004). The two ends of the viral RNA promoter are
bound by two sites proximal to these nucleotide binding motifs
(Jung and Brownlee, 2006; Li et al., 1998); however, other
studies indicate that the N-terminus may also be involved
(González and Ortín, 1999a). Regions overlapping these sites
have also been implicated in binding to the cRNA promot-
er (González and Ortín, 1999b). In addition to these active
sites, binding sites for the PA and PB2 subunits are located at the
N- and C-termini, respectively. While the former has been de-
fined as the 48 N-terminal amino acids (Perez and Donis, 1995,
2001), the latter has been located within the 150 C-terminal
amino acids (González et al., 1996; Ohtsu et al., 2002; Toyoda
et al., 1996), althoughmore recent studies suggest the last 45–75
amino acids are sufficient for binding (Poole et al., 2004, 2007).
The proposed endonuclease active site (residues 508–522)
contains two glutamic acid and one aspartic acid residues (E508,
E519 and D522), which are apparently crucial for endonuclease
cleavage (Li et al., 2001). The location of this site, between the
central transcription motifs and the PB2-binding site, indicates
that the C-terminal half of PB1 may play a principal role in the
priming of mRNA synthesis. However, despite the proximity of
these two active sites, they can both function independently—
endonuclease activity can occur without RNA synthesis and vice
versa. The polymerase is also capable of binding capped RNA in
the presence of the 5′ vRNA promoter alone; however, both
strands of the vRNA promoter are required for efficient
endonuclease activity (Hagen et al., 1994). According to later
reports, binding of the viral polymerase to the 3′ end of the
vRNA is not an absolute requirement for endonuclease activity
(Lee et al., 2003), in particular when a capped RNA substrate
contains a CA cleavage site (Rao et al., 2003). Conformational
changes in the polymerase complex upon promoter binding have
been suggested as a mechanism for activation of the cap binding
and endonuclease sites (Lee et al., 2003).
In a previous study, analysis of the primary sequence of PB1
of influenza A/WSN/33 virus by PSORT II resulted in a
prediction that a C-terminal region of PB1, 668-PKRNRSI-674,
could function as a nuclear localization signal (NLS) (Fodor and
Smith, 2004). A K669A/R670A double mutation in this region
has been constructed and it was shown that this mutation did not
affect the intracellular localization of PB1. Surprisingly, the
mutation affected polymerase activity — while RNA replica-
tion was increased, RNA transcription was decreased. Since the
regulation of these processes is poorly understood, we decided
to investigate this effect further. In addition to the previouslyconstructed double mutant, single mutants were prepared by
mutating positively charged residues at this site to alanines
(K669A, R670A and R672A) by site-directed mutagenesis.
Each of these residues is conserved in over 99% of influenza A
and B viruses. We show that these mutations inhibit the process
of priming mRNA transcription and, in the case of the K669A
and R672A, cause attenuation when incorporated into recom-
binant viruses. We suggest that this region of PB1 is involved in
the regulation of viral mRNA transcription by playing a role in
vRNA promoter and cap binding.
Results
Mutations in the PB1 subunit of the influenza polymerase affect
transcription and replication differentially
A double mutant in the C-terminus of PB1 (K669A/R670A)
was previously constructed to study the sequence requirements
for nuclear localization of PB1 (Fodor and Smith, 2004).
Although this mutation did not affect nuclear localization, a
differential effect on the activities of the RNA polymerase
complex was observed. In a cell-based RNP reconstitution ex-
periment, accumulation levels of the RNA replication products
were increased, whereas the accumulation level of viral mRNA
was reduced. These results suggested that this region of PB1
might be involved in the differential regulation of RNA tran-
scription and replication. To investigate this further, three single
point mutants were constructed in this region by site-directed
mutagenesis of the PB1 gene.
In order to evaluate the effect of these mutations on
polymerase activity, mutant PB1 subunits were coexpressed
with the other polymerase subunits, NP and a plasmid encoding
the genomic influenza segment 6 (NA) to form RNP complexes
in vivo. After 24 h total RNA was isolated and the levels of
vRNA, cRNA and mRNAwere assayed by primer extension. In
the absence of trimeric polymerase and NP only low levels of
input vRNA, transcribed by cellular RNA polymerase I, were
observed (Fig. 2A, lane 1). In cells expressing wild-type
polymerase and NP the input vRNA has been amplified by the
viral polymerase via cRNA and it has been transcribed into
mRNA as reported previously (lane 2) (Fodor et al., 2002).
Expression of the K669A/R670A double mutant resulted in a
significant decrease (significant to pb0.001 in a one-sample
Student's t test) in mRNA levels (10% of wild type). In contrast,
a significant (pb0.01) increase in cRNA levels was observed
(196% of wild type). These results are consistent with the
previous results of Fodor and Smith (2004) using a chimeric
NS-CAT template (encoding a CAT reporter gene with the ends
of segment 8). mRNA levels for the PB1 single mutants,
K669A, R670A and R672A, were also reduced (75%, 54% and
53% of wild type, respectively), while there was an increase in
the amount of cRNA detected (significant to pb0.05 in the case
of R672A). No significant effect on the accumulation levels of
vRNAwas observed for any of the mutants analyzed. Although,
the R670A single mutant caused an apparent up-regulation of
vRNA levels, this was not statistically significant. Similar
results have been observed when RNP complexes containing
Fig. 2. Effect of mutations in the C-terminus of PB1 on viral RNA levels produced
in an in vivo recombinant influenzaRNP reconstitution system. RNAwas extracted
from 293T cells transfected with expression plasmids encoding PB2, PA, NP and
PB1 (WT or mutants) and a pPOLI plasmid expressing the influenza segment 6
(NA) as a template. Primer extension products were separated by 6% PAGE in 7M
urea and detected by autoradiography. Primer extension products for mRNA,
cRNA and vRNA transcripts are as indicated; 5S rRNA levels were used as an
internal control. (B) Quantitation of mRNA (dark grey bars), cRNA (light grey
bars) and vRNA (white bars) is shown. Results have been normalized using the 5S
rRNA signal and expressed as a percentage of wild-type activity with standard
deviations as shown. Quantitation was based on three independent experiments.
Fig. 3. Effect of mutations in the C-terminus of PB1 on the growth properties of
recombinant influenza viruses. (A) Growth curves of WT or mutant recombinant
influenza A/WSN/33 viruses possessing mutations in their PB1 gene segment.
Samples of culture medium were collected from infected MDBK cells every 12 h
and viral titers determined by plaque assay. Means and standard deviations of three
independent experiments are shown. (B) Analysis of RNA levels during viral
infection ofMDBK cells at anMOI of 1. Levels of segment 6 (NA) mRNA, cRNA
and vRNA and cellular 5S rRNAwere detected by primer extension. Products were
separated by electrophoresis on a 6% polyacrylamide/7M urea gel and detected by
autoradiography. (C) Ratios of quantitated levels of mRNA to cRNA. Quantitation
of RNA levels was performed by phosphorimaging analysis. Results shown with
standard deviations are based on three independent experiments.
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segment 6 in vivo (results not shown). Taken together, these
results suggest that this region of PB1 is involved in the
differential regulation of the vRNA-templated transcriptional
and replicative activities of the RNA polymerase.
Recombinant mutant viruses are attenuated by an inhibition of
mRNA transcription
To investigate this differential effect in the context of viral
infection attempts were made to rescue the three point mutations
and the double mutation using plasmid-based reverse genetics
(Fodor et al., 1999; Neumann et al., 1999). However only viruses
incorporating the K669A and R672A mutations were success-
fully produced; despite several attempts, no infectious particles
incorporating the R670A point mutation and K669A/R670A
double mutation were observed. Since the double mutationinduced a strong inhibition of mRNA levels in the RNP recon-
stitution assay above, this latter result was not unexpected.
However, none of the RNA levels of the R670A mutant were
significantly different from wild type, therefore absence of
infectious particles is perhaps surprising. Rescued viruses were
amplified by 2 passages on MDBK cells and the presence of
mutations introduced was confirmed by RT-PCR and sequencing.
205P.S. Kerry et al. / Virology 373 (2008) 202–210Growth properties of the K669A and R672A recombinant
viruses were assayed by infection of MDBK monolayers. Every
12 h an aliquot of the culture media was harvested and the
concentration of infectious virus established by plaque assay.
The growth of both mutant viruses was significantly attenuated
compared to the wild-type A/WSN/33 virus (Fig. 3A) [the area
under each growth curve was compared in a two-tailed Student's
t test (pb0.01)]. Additionally, the mean plaque diameter was
also reduced for both recombinant viruses. Wild-type influenza
A/WSN/33 virus produced plaques 1.09±0.17 mm in diameter,
whereas both K669A and R672A viruses showed significantly
smaller plaques at 0.68±0.18 mm and 0.66±0.18 mm respec-
tively (both pb0.001 in two-tailed Student's t tests).
To determine the activity of polymerase complexes formed in
vivo during an infection, semi-confluent dishes of MDBK cells
were infected at an MOI of 1 and RNAwas harvested 6 h post
infection. The levels of each of the three viral RNA species of the
NA segment were assayed by primer extension (Fig. 3B) and as a
comparison of the relative levels of transcription and replication,
the ratio of signal from mRNA and cRNA was calculated
(Fig. 3C). For wild-type A/WSN/33 virus, this ratio was 7.0±
1.1, however for the K669A and R672A viruses this ratio was
strongly and significantly reduced to 2.6±0.5 and 1.2±0.2 (both
pb0.001 in two-tailed t tests). At a later time point post infection
(9 h) a further reduction in the mRNA to cRNA ratio was
observed as the accumulation levels of cRNA increased, but the
levels of mRNA remained unchanged. Similar results were
observed by analyzing the PA-specific viral RNAs by primer
extension assay (results not shown). Taken together, these results
in the context of viral infection indicate a shift from transcription
towards replication, similar to that observed in the RNP recon-
stitution assay (see above).
Mutations in the PB1 subunit inhibit transcription in vitro
To investigate the molecular basis of these effects in more
detail, we employed an in vitro approach using partially purified
recombinant polymerase complexes. This allowed the analysis
of the processes involved in the stages of transcription and
characterization of the nature of the inhibition observed. To this
end, polymerase complexes were purified using the tandem
affinity purification (TAP) method from 293T cells transientlyFig. 4. (A) Tandem affinity purification of influenza polymerase from 293T cells
transfected with expression plasmids for combinations of PB2-TAP, PA and
wild-type or mutant PB1 subunits. Purified proteins were separated by 8%
PAGE-SDS and detected by staining with silver. Sizes of protein standards in
kilodaltons are shown on the left; positions of polymerase protein bands are on
the right, as indicated. During purification part of the TAP tag was cleaved from
PB2 by TEV protease. (B–D) Activity of purified polymerase complexes
assayed in vitro, by RNA synthesis primed with (B) globin mRNA as a cap
donor or (C) the dinucleotide ApG or (D) a radiolabeled, capped oligonucleo-
tide. Separation was performed by 20% PAGE in 7 M urea and transcription
products were detected by autoradiography. Transcription products (TP) are as
indicated. Multiple products detected in panel B are likely to be due to
heterogeneity in the globin mRNA preparation. (E) Quantitation of the results
from panels B–D, as performed by phosphorimaging analysis. Quantitated data
were expressed as a percentage of wild-type activity. Means and standard
deviations of four independent sets of data are shown.expressing the polymerase proteins including a TAP-tagged PB2
subunit (see Materials and methods). To assess the formation
of complexes containing mutant PB1 subunits, preparations
purified using a TAP-tagged PB2 subunit were analyzed by
SDS-PAGE and staining with silver (Fig. 4A). All three poly-
merase proteins were detected in wild-type and mutant
polymerase complexes (lanes 2–6), indicating that these mutants
have no detectable effect on complex formation, an important
consideration, considering that these mutations are located in or
close to the proposed PB2-binding site (González et al., 1996;
Ohtsu et al., 2002; Poole et al., 2004, 2007; Toyoda et al., 1996).
Fig. 5. Effect of point mutations in the C-terminus of PB1 on binding of influenza
polymerase complexes to the viral RNA promoter or a capped oligonucleotide.
UV Crosslinking was performed with partially purified polymerase complexes
and (A) 32P-labeled 5′ model promoter or (B) 32P-labeled 3′ model promoter in
the presence of 0.5 pmol unlabeled 5′model promoter or (C) 32P-labeled capped
oligoribonucleotide in the presence of 0.5 pmol each unlabeled 3′ and 5′ model
promoter. After crosslinking, the complexes were denatured and separated by 8%
PAGE-SDS. Detection of protein bands was performed by autoradiography. Size
of protein standards in kilodaltons is shown on the left. The covalent attachment
of the short RNA oligonucleotide induces a mobility shift of approximately
10 kDa. (D) Quantitation of crosslinked products from panels A–C by
phosphorimaging analysis. Binding activity of the mutants is expressed as a
percentage of wild-type activity. Means and standard deviations of at least three
independent experiments are shown.
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assayed using a model RNA template and rabbit globin mRNA
supplied as a cap donor. Transcription products of approxi-
mately 25–30 nucleotides in length were produced when wild-
type polymerase complexes were included (Fig. 4B, lane 2).
Transcriptional activity of complexes containing mutant PB1
subunits was reduced to below 30% of wild type in all cases
(significant to pb0.001 in one-sample Student's t tests), al-
though the K669A/R670A and R672A mutant polymerases
were most severely inhibited.
Next, the ability of the purified polymerases to elongate
independent of priming with capped RNAwas assayed using the
dinucleotide ApG to prime transcription, generating a 14-nt
transcription product (Fig. 4C, lane 2). The activity of three of
the mutants (K669A/R670A, K669A, R672A) was significantly
reduced from wild type in one-sample Student's t tests, whereas
the remaining mutant (R670A) was not significantly reduced
from wild type. However, the reduction in activity was not as
severe as observed in globin mRNA-primed transcription, with
all mutants displaying at least 30% of wild-type activity. There-
fore, the more severe inhibition of cap-dependent transcriptional
activity could be caused by a block in cap binding or endo-
nuclease activity.
To address these possibilities, we assayed for transcriptional
activity using a capped oligonucleotide with [α-32P]-GTP incor-
porated into the cap structure. Transcriptional activity in this
assay is dependent on binding to a capped primer but inde-
pendent of endonuclease activity. In the presence of this capped
oligonucleotide mutant polymerase complexes showed signifi-
cantly reduced levels of activity ( pb0.05 as calculated by one-
sample Student's t test, Fig. 4D). This effect is consistent with a
defect of these RNApolymerases in transcription reactions using
globin mRNA as a cap donor (see above) and suggests that the
cap-binding activity of these mutants might be affected.
Binding of the mutant polymerases to the influenza vRNA
promoter and capped oligoribonucleotides
The results above suggest that the PB1 mutations might
specifically affect binding to the cap structure of host mRNAs.
Since binding to capped RNA is dependent on the association of
the viral RNA polymerase with the vRNA template (Hagen
et al., 1994), the extent to which promoter binding might be
affected must be assessed. To investigate this, UV crosslinking
reactions were performed between partially purified recombi-
nant RNA polymerase complexes and either 32P-labeled 5′
model promoter alone or 32P-labeled 3′ model promoter in the
presence of unlabeled 5′ model promoter. When the labeled 5′
model promoter was crosslinked to a wild-type polymerase two
bands were observed (Fig. 5A, lane 2). These were identified as
PB1 and co-migrating bands of PA and PB2-TAP by immuno-
precipitation (data not shown), in agreement with a previous
report (Fodor et al., 1994). When the mutant polymerase
complexes were used in the crosslinking assay, the intensities of
the polymerase bands were not significantly altered, suggesting
that these mutations have no effect on the binding of the
polymerase complex to the 5′ end of the vRNA promoter.Crosslinking reactions were also performed using a 32P-
labeled 3′model promoter in the presence of unlabeled 5′model
promoter (Fig. 5B). Again two bands were observed and
identified as PB1 and co-migrating bands of PA and PB2-TAP
by immunoprecipitation (data not shown), in accordance with
previous reports (Fodor et al., 1993; Hara et al., 2006; Maier
et al., 2008). Three of the mutant polymerase complexes
(K669A/R670A, K669A, R672A) were significantly ( pb0.01,
one-sample t test) reduced in their binding to the 3′ end of the
vRNA promoter, however binding by the R670A mutant poly-
merase was not reduced. The levels of 3′ end vRNA promoter
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observed in ApG-primed transcription and thus may explain the
reduction in activity observed. However, the inhibition of 3′ end
vRNA promoter binding alone could not fully explain the
reduction in transcription observed when capped substrates are
used.
In order to analyze this further, we assayed the binding of
the RNA polymerase to the 32P-labeled, capped oligonucleotide
by UV crosslinking in the presence of the vRNA promoter
(Fig. 5C). No radiolabeled crosslinked products were observed
in the absence of viral RNA polymerase (lane 1). A radiolabeled
band at the expected position of the PB2 subunit of the RNA
polymerase was observed if a wild-type RNA polymerase was
used. The binding of all mutant RNA polymerase complexes
was strongly reduced (significant to pb0.01). The inhibition of
binding to capped oligonucleotides was much greater than that
observed for binding to the 3′ end of the vRNA promoter and
more closely reflects the inhibition of in vitro transcription
primed by capped globin mRNA.
Discussion
The C-terminal half of the PB1 subunit of the influenza virus
RNA-dependent RNA polymerase has been proposed to be
involved in promoter binding, endonuclease cleavage of host
mRNA and binding to the PB2 subunit (which itself binds the
cap structures of host mRNAs). These activities suggest that this
region is particularly important in the regulation of viral mRNA
synthesis. We have investigated this region further, by mutation
of three highly conserved, positively charged residues to alanine
in single and one double mutation, and observed a differential
effect on viral transcription and replication.
Initially, to determine the effect of these mutations on
polymerase activity they were reconstituted into RNP com-
plexes in vivo by transfection of 293T cells. A differential effect
was observed, most apparent in the case of the double mutant,
K669A/R670A, which displayed barely detectable mRNA
levels and cRNA levels almost twice those of wild type. Pre-
viously a similar, but less pronounced, effect was observed using
a synthetic NS-CAT template (Fodor and Smith, 2004). In this
previous study, cells expressing recombinant NS-CAT RNPs
were incubated for longer (40 h) than the NA RNPs used here
(24 h) possibly leading to an accumulation of the RNA products
that could have masked initial more pronounced differences.
In order to investigate the relevance of this differential effect
on RNA levels in the context of a viral infection, we attempted to
rescue recombinant viruses incorporating these mutations into an
influenza A/WSN/33 virus background. When the K669A and
R670A mutations were incorporated into recombinant viruses,
they displayed an attenuated phenotype entirely consistent with
the inhibition of transcription observed both in the RNP
reconstitution assay and when purified polymerase complexes
were analyzed in vitro. Although the levels of replication
products were decreased compared to wild type, this is likely to
be the result of reduced viral mRNA synthesis. Reduction in viral
mRNA synthesis could lead to limiting levels of viral RNA
polymerase and NP during viral infection resulting in degrada-tion of replication products (Vreede et al., 2004). In the RNP
reconstitution assay, viral polymerase and NP are provided by
protein expression plasmids and therefore viral RNA replication
is independent of viral mRNA transcription. Taken together, both
mutant viruses showed decreased relative accumulation levels of
mRNA compared to the replication intermediate cRNAwhich is
fully consistent with a defect in viral mRNA transcription.
Unfortunately, the other point mutant (R670A) and the double
mutant could not be rescued. As described earlier, the effect of the
double mutant on mRNA levels was severe, and this probably
prevented viral rescue. Of the three single point mutants, the
R670A mutation had the smallest effect in vitro and thus it is
somewhat surprising that this mutation was unable to be rescued.
We can only speculate that the changes made in the RNA se-
quence to produce this mutation may have an additional effect on
packaging signals operating within the coding region of the gene.
The molecular mechanism of the inhibition of mRNA tran-
scription caused by these mutations was investigated using a
series of in vitro transcription assays designed tomimic the stages
of the process of transcription. Initially transcription was primed
using rabbit globin mRNA as a source of capped substrates. For
transcription to occur, the polymerase complexmust first bind the
model vRNA promoter and the globin mRNA, then cleave the
globin mRNA to provide an oligonucleotide primer, before
elongating along the 3′ end of the promoter. Therefore inhibition
of any of these steps could lead to the inhibition of transcription
observed. In order to analyze the requirement for endonuclease
activity, the rabbit globin mRNA was replaced by a capped
oligonucleotide, which does not require cleavage to be used as a
primer. Although activity was somewhat increased, transcription
remained significantly inhibited in all cases. Also, the mutant
polymerase complexes were more inhibited when a capped
oligonucleotide was used than when the uncapped ApG dinu-
cleotide was used to prime transcription. This indicated that a
direct effect on binding to capped substrates could be responsible
for the inhibition. We investigated this further by UV cross-
linking between the purified recombinant polymerases and the
capped oligonucleotide, where all four mutant polymerases
displayed decreased binding to an extent consistent with the
inhibition of transcription observed when globin mRNA was
used as a primer. This decrease in binding may appear surprising,
since the binding site for the cap structure has previously been
located in the PB2 subunit, however it should be considered that
the capped oligonucleotide will extend from the cap binding site
into the PB1 subunit to the endonuclease active site and the
polymerase active site for transcription to occur. Hence an
obstruction between these locations in the polymerase complex
will inevitably result in destabilizing binding to the capped
oligonucleotide and therefore decrease the binding observed by
crosslinking. The mutations investigated here are within or close
to the proposed PB2 binding site (González et al., 1996; Ohtsu
et al., 2002; Poole et al., 2004, 2007; Toyoda et al., 1996) and
close to the reported endonuclease active site (Li et al., 2001).
Thus these residues are well situated in the primary sequence for
such an effect to occur.
An additional effect of these mutations was a decrease in
binding to the 3′ end of a model vRNA promoter, as assayed by
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studies implicating this region in binding to the vRNA promoter
(González and Ortín, 1999a). This reduction in vRNA binding is
the likely cause of the reduced activity observed when ApG is
used as a primer for transcription, as the extent of inhibition of
transcription is similar to the reduction in binding to the 3′ end of
the vRNA template. This inhibition of promoter binding may
appear incompatible with the increase in cRNA levels observed
in the RNP reconstitution assay as a decrease in promoter
binding ought to lead to a decrease in all aspects of polymerase
activity. However, this discrepancy could be due to a stabilizing
effect in the in vivo assay caused by the longer template and the
presence of NP forming a complete RNP. The RNP structure is
likely to be more stable than the polymerase–promoter complex
investigated in the in vitro assays. Therefore, these PB1 muta-
tions may have a weaker inhibitory effect on vRNA promoter
binding in the context of RNPs.
Since the binding of polymerase complexes to capped sub-
strates is dependent on the complex first binding to the vRNA
promoter, we cannot exclude that the reduction in promoter
binding is the cause of the reduction in binding to the capped
oligonucleotide. However, these mutations do not appear to
affect binding to the 5′ strand of the promoter, which has been
shown to be sufficient for binding to capped substrates in pre-
vious studies (Cianci et al., 1995). Additionally, the inhibition of
transcription primed by capped oligonucleotides appears to be
distinct from the effect on promoter binding, as the binding of the
R670A mutant to either strand of the vRNA promoter is indis-
tinguishable from wild type, yet binding to capped oligonucleo-
tides is severely inhibited (Fig. 5D). In addition, in the RNP
reconstitution assay the K669A/R670A double mutant displays
significantly increased levels of the primer-independent product
cRNA, while having significantly reduced levels of the primer-
dependent product mRNA (Fig. 2B). Therefore, it is likely that
binding to capped substrates is affected directly and not indirectly
via an inhibition of vRNA promoter binding. However, it remains
possible that these two effects may be related, as the 3′ end of the
cleaved capped oligonucleotide must align with the 3′ end of the
vRNA promoter for priming to occur and thus a mutation that
affects the binding of the capped oligonucleotide may also affect
its alignment with the 3′ end of the vRNA promoter.
In summary, point mutations in the C-terminus of the PB1
subunit were found to affect both vRNA promoter binding and
binding to capped RNA substrates. This inhibition leads to a
reduced transcription observed in both in vivo and in vitro assays
using recombinant viruses and purified polymerase complexes.
We suggest that this region of PB1 is involved in the regulation of
mRNA transcription, in addition to the endonuclease active site
and promoter-binding sites previously identified in this region.
Materials and methods
Plasmids
The protein expression plasmids pcDNA-3A, pcDNA-PB1,
pcDNA-PB2, pcDNA-PA, pcDNA-NP and pcDNA-PB2-TAP
have been described previously (Carr et al., 2006; Deng et al.,2005; Fodor et al., 2002). The pPOLI-PB1-RT, pPOLI-PB2-RT,
pPOLI-PA-RT, pPOLI-HA-RT, pPOLI-NP-RT, pPOLI-NA-RT,
pPOLI-M-RT and pPOLI-NS-RT RNA expression plasmids
have also been described (Fodor et al., 1999). The pcDNA-PB1-
K669A/R670A double mutant plasmid has been described
elsewhere as pcDNA-PB1-NLS3 (Fodor and Smith, 2004). The
K669A/R670A doublemutation andK669A, R670A andR672A
single point mutations were engineered into pcDNA-PB1 and
pPOLI-PB1-RT by site-directed PCR mutagenesis using appro-
priate primers andwere confirmed by full sequencing of the gene.
All primer sequences are available upon request.
RNP reconstitution assay
Human embryonic kidney (293T) cells in 35-mm dishes were
transfected in suspensionwith 1μg each of pcDNA-PB2, pcDNA-
PA, pcDNA-NP, pPOLI-NA-RTand 1 μg of pcDNA-PB1 (WTor
mutants) using 10 μl Lipofectamine 2000 reagent (Invitrogen) in
1.5 ml minimal essential medium (MEM) containing 10% fetal
calf serum (FCS). As a negative control, 4 μg of empty pcDNA-
3A vector (Invitrogen) was transfected instead of the pcDNA
expression plasmids. Twenty-four hours post transfection total cell
RNA was isolated using TRIzol reagent (Invitrogen) and primer
extension analysis of isolated RNA was performed as described
previously (Fodor et al., 2002). Briefly, RNA was reverse
transcribed using SuperScript II reverse transcriptase (Invitrogen)
with two radiolabeled NA-specific primers and one primer for the
host 5S rRNA as an internal control as described previously (Hara
et al., 2006; Vreede et al., 2004). Transcription products were
separated on 6% polyacrylamide gels containing 7 M urea and
detected by autoradiography. Quantitation was performed using a
Fujifilm FLA-5000 fluorescent image analyzer and Fujifilm
imaging plates. Data from 3 independent experiments were
collected and analyzed in AIDA software (Raytest). In each
experiment, the wild-type RNA levels were set as 100% and RNA
accumulation levels of themutants were expressed as a percentage
of that of the wild type. Values were converted to mean percentage
using Excel (Microsoft). The significance of the data was tested
using a two-tailed one-sample t test.
Generation and amplification of recombinant viruses
The plasmid-based rescue technique (Fodor et al., 1999,
2003; Neumann et al., 1999) was used to generate recombinant
influenza A/WSN/33 viruses incorporating point mutations
into the PB1 gene segment. Briefly, mutant pPOLI-PB1-RT
plasmids were transfected into 293T cells in suspension with 7
pPOLI plasmids encoding the other 7 viral gene segments,
using Lipofectamine 2000. The three influenza polymerase
proteins and the nucleoprotein were expressed from pcDNA-
PB1, -PB2, -PA and -NP, respectively. Virus collected 48 h
post transfection was amplified for a further 2–3 days on
MDBK cells.
WT and mutant A/WSN/33 viruses were used to infect
MDBK cells grown as monolayers in 35-mm dishes at an MOI
of 0.0001. Aliquots of released virus were collected from the
medium every 12 h and plaque assayed on MDBK cells to
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two-tailed Student's t tests were performed comparing the area
under each curve.
For measurement of plaque size viral plaques were stained
with a Coomassie brilliant blue solution (0.25% Coomassie,
50% methanol, 10% acetic acid). The size of about 40 to 60
plaques for each virus was determined using Metamorph
software and expressed as arithmetic means with standard
deviations. Two-tailed t tests were performed to determine the
significance of the results.
Analysis of vRNA, mRNA and cRNA by primer extension
Analysis of RNA levels during infection was performed as
previously (Carr et al., 2006), with slight modifications. MDBK
cells grown in monolayers were infected with wild-type or
recombinant influenza A/WSN/33 viruses at an MOI of 1. At 6
and 9 h post infection total cell RNA was harvested using
TRIzol (Invitrogen). RNA species were detected by primer
extension (as for RNP reconstitution assay). The ratio of signal
intensity from the mRNA and cRNA bands was calculated
using Excel (Microsoft) and compared using a two-sample
(unequal variance) two-tailed t test.
Affinity purification of polymerase proteins for in vitro analysis
Polymerase proteins were purified according to the tandem
affinity purification (TAP) protocol, using a TAP-tagged PB2
subunit (Deng et al., 2005; Puig et al., 2001). Briefly, 293T cells
in 100-mm dishes were transfected in suspension with either 5 μg
each of pcDNA-PB2-TAP, pcDNA-PA and pcDNA-PB1 (WT or
mutants) or 15 μg pcDNA-3A using 30 μl Lipofectamine 2000
reagent. Cells were harvested 40 h post transfection and lysates
prepared using 1 ml HEPES lysis buffer [200 mM NaCl, 50 mM
HEPES (pH 8.0), 1 mM PMSF, 25% glycerol, 0.5% IGEPAL
CA-630, 0.05% β-mercaptoethanol, 1× complete protease
inhibitor cocktail (Roche)]. Polymerase complexes were purified
by incubation of 800 μl of lysate with 70 mg of immunoglobulin G
(IgG)-sepharose beads (approximately 60 mg dry weight) at 4 °C
for 2 h in a final volume of 4.4 ml. The IgG-sepharose beads were
washed 2 times with 5 ml wash buffer [150 mM NaCl, 10 mM
HEPES (pH 8.0), 0.1 mM PMSF, 10% glycerol, 2% IGEPAL
CA-630] and once in 5 ml cleavage buffer (as wash buffer with
1 mMDTT). Complexes were released from the IgG-sepharose
beads by cleavage with 15 U Tobacco Etch Virus (TEV) protease
in 100 μl cleavage buffer at 16 °C for 2 h and stored at −80 °C
after the addition of 50 μl 80% glycerol. Yield and purity
were assessed by 8% SDS-PAGE and detection by Proteosilver
(Sigma). Approximately equal levels of polymerase proteins
were detected in each preparation and therefore approxi-
mately equal amounts of protein were used in the in vitro activity
assays.
Preparation of radiolabeled oligoribonucleotides
The model vRNA promoter 3′ and 5′ oligonucleotides (5′
GGCCUGCUUUUGCU 3′ and 5′ AGUAGAAACAAGGCC3′, respectively) were 32P-labeled using polynucleotide kinase
(Roche) and [γ-32P]-ATP as described previously (Fodor et al.,
2002).
A 5′ diphosphorylated oligonucleotide (ppAmAmAmUACU-
CAAG, synthesis described in Brownlee et al., 1995) was
capped using [α-32P]-GTP and guanylyl transferase (Ambion)
as described previously (Fodor et al., 2002).
In vitro transcription activity assays
In vitro transcription assays were performed as described (Fodor
et al., 2002), with modifications. Reactions were performed in a
final volume of 6 μl including 3 μl partially purified polymerase
with 10 μmol of synthetic model vRNA promoter [an equimolar
mixture of 3′ (5′ GGCCUGCUUUUGCU 3′) and 5′ (5′
AGUAGAAACAAGGCC 3′) vRNA promoter ends (both
Dharmacon)] in the presence of 5 mM MgCl, 3.3 mM DTT,
10URNasin (Promega), 1mMATP, 0.5mMCTP, 1mMApG and
1.5 μCi [α-32P]-GTP (Amersham). In globin mRNA-primed in
vitro transcription assays, the ApG was replaced with 50 ng rabbit
globin mRNA (Sigma). For RNA synthesis primed by the capped
oligonucleotide (see above), the [α-32P]-GTP and ApG were
replaced by 0.5 mM unlabeled GTP and 5×103 cpm of the
radiolabeled oligonucleotide. Reactionswere incubated at 30 °C for
90 min and terminated by the addition of 6 μl 90% form-
amide containing 10 mM EDTA, bromophenol blue and xylene
cyanol dyes and incubation at 99 °C for 5 min. The radiolabeled
products were separated on 20%PAGE/7MUrea gels and detected
by autoradiography. Quantitation and statistical analysis were
performed as described for the RNP reconstitution assay (see
above).
UV crosslinking of labeled RNA probes to polymerase
complexes
UV crosslinking was used to assay binding of the viral
RNA polymerase to the vRNA promoter and capped-RNA
substrates as previously (Fodor et al., 2002; Hara et al., 2006).
Briefly, binding reactions were preformed in a final volume of
10 μl containing 5 μl partially purified polymerase complexes
with either 5×104 cpm of 32P-labeled 3′ model promoter end
in the presence of 5 pmol 5′ model promoter end or
1×105 cpm of 32P-labeled 5′ model promoter end alone in a
binding buffer containing 100 mM KCl, 10 mM HEPES (pH
8.0), 2 mM MgCl2, 1 mM DTT, 0.5 mM EGTA (pH 8.0), 8 U
RNasin, 10% glycerol. For crosslinking to a capped oligonu-
cleotide (see above), the labeled 3′ model promoter was
replaced with 5 pmol unlabeled 3′ model promoter and 1×105
cpm radiolabeled capped oligonucleotide. Reaction mixtures
were incubated at 30 °C for 30 min then transferred to a
96-well plate on ice and irradiated with UV light (254 nm)
for 10 min in a UV stratalinker (Stratagene). The irradiated
samples were analyzed by 8% SDS-PAGE and cross-
linked products detected by autoradiography. Quantitation
of crosslinked products and statistical analysis were
performed as described for the RNP reconstitution assay
(see above).
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